Get the Stockscreener App
5.325
0.28%
-0.015
Curevac N V stock is traded at $5.325, with a volume of 842.34K.
It is down -0.28% in the last 24 hours and down -2.29% over the past month.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
See More
Previous Close:
$5.34
Open:
$5.32
24h Volume:
842.34K
Relative Volume:
1.68
Market Cap:
$1.19B
Revenue:
$596.48M
Net Income/Loss:
$123.72M
P/E Ratio:
9.7101
EPS:
0.5484
Net Cash Flow:
$106.59M
1W Performance:
-1.02%
1M Performance:
-2.29%
6M Performance:
+49.58%
1Y Performance:
+92.93%
1-Day Range:
$5.29
$5.36
1-Week Range:
$5.29
$5.38
52-Week Range:
$2.37
$5.72
Curevac N V Stock (CVAC) Company Profile
Compare CVAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.325 | 1.20B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.29 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.61 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.49 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
823.27 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.17 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-25-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-08-23 | Initiated | SVB Securities | Outperform |
| Jan-19-23 | Upgrade | UBS | Neutral → Buy |
| Jan-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Jun-17-21 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Underperform |
| Apr-26-21 | Initiated | Guggenheim | Neutral |
| Dec-10-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Sep-08-20 | Initiated | Credit Suisse | Neutral |
| Sep-08-20 | Initiated | Jefferies | Hold |
View All
Curevac N V Stock (CVAC) Latest News
BioNTech (NASDAQ: BNTX) reports €1,518.9M revenue, net loss €28.7M; raises FY outlook - Stock Titan
Relative strength of CureVac N.V. in sector analysisMarket Movers & AI Enhanced Execution Alerts - newser.com
Understanding CureVac N.V.’s price movementPortfolio Value Summary & High Accuracy Trade Signal Alerts - newser.com
Smart tools for monitoring CureVac N.V.’s price actionBuy Signal & Safe Capital Preservation Plans - newser.com
Historical volatility pattern of CureVac N.V. visualizedQuarterly Profit Report & Fast Gain Swing Trade Alerts - newser.com
Using data tools to time your CureVac N.V. exitJuly 2025 Short Interest & Verified High Yield Trade Plans - newser.com
How interest rate cuts could boost CureVac N.V. stockMarket Risk Summary & Weekly Momentum Stock Picks - newser.com
Will CureVac N.V. stock benefit from green energy trendsMarket Growth Report & Real-Time Volume Analysis - newser.com
Why CureVac N.V. stock is a value investor pickWeekly Trend Report & Verified Technical Trade Signals - newser.com
Can CureVac N.V. stock resist market sell offsRisk Management & Technical Confirmation Alerts - newser.com
How currency fluctuations impact CureVac N.V. stock2025 AllTime Highs & Free Reliable Trade Execution Plans - newser.com
Is CureVac N.V. stock positioned for digital transformation2025 EndofYear Setup & Growth Focused Stock Pick Reports - newser.com
CureVac’s New mRNA Study: A Potential Game-Changer in Lung Cancer Treatment - MSN
CureVac Announces Extraordinary Meeting for Merger with BioNTech - MSN
CureVac N.V. (NASDAQ:CVAC) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Is CureVac N.V. stock supported by strong fundamentalsOptions Play & Safe Capital Growth Plans - Fundação Cultural do Pará
Analyzing net buyer seller activity in CureVac N.V.Options Play & Precise Trade Entry Recommendations - newser.com
Is CureVac N.V. stock ready for breakoutMarket Activity Report & Risk Controlled Swing Trade Alerts - fcp.pa.gov.br
CureVac schedules extraordinary shareholder meeting for November 25 By Investing.com - Investing.com South Africa
CureVac schedules extraordinary shareholder meeting for November 25 - Investing.com
CureVac schedules extraordinary meeting; releases proxy and merger docs - Stock Titan
Curevac N V Stock (CVAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):